Vertex Pharmaceuticals Inc
NASDAQ:VRTX

Watchlist Manager
Vertex Pharmaceuticals Inc Logo
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Watchlist
Price: 491.89 USD -0.55% Market Closed
Market Cap: 127B USD
Have any thoughts about
Vertex Pharmaceuticals Inc?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

26.8
Current
19.4
Median
4.3
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
26.8
=
Enterprise Value
120.3B USD
/
EBITDA
4.5B USD
All Countries
Close
Market Cap EV/EBITDA
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.8B USD 26.8
FR
Pharnext SCA
OTC:PNEXF
6T USD -216 796.7
US
Abbvie Inc
NYSE:ABBV
300.2B USD 14.8
US
Amgen Inc
NASDAQ:AMGN
158.7B USD 17.5
US
Gilead Sciences Inc
NASDAQ:GILD
115B USD 10.1
US
Epizyme Inc
F:EPE
94.1B EUR -521.2
AU
CSL Ltd
ASX:CSL
137.3B AUD 20.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
88.3B USD 17.4
US
Seagen Inc
F:SGT
39.3B EUR -59.5
NL
argenx SE
XBRU:ARGX
34.1B EUR -104.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
33.6B USD -240.8
EBITDA Growth
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Average EV/EBITDA: 17.9
26.8
38%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 796.7 N/A
US
Abbvie Inc
NYSE:ABBV
14.8
28%
US
Amgen Inc
NASDAQ:AMGN
17.5
63%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.2 N/A
AU
CSL Ltd
ASX:CSL
20.8
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.5 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -240.8 N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
90.5
2-Years Forward
EV/EBITDA
21.5
3-Years Forward
EV/EBITDA
19.2

See Also

Discover More